Business Description
Jaguar Health Inc
NAICS : 325412
SIC : 2834
ISIN : US47010C8881
Total Employee Number:
47Description
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | -0.38 | |||||
Debt-to-Equity | -3.09 | |||||
Debt-to-EBITDA | -1.33 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -17.35 | |||||
Beneish M-Score | -4.25 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 91.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 18.26 | |||||
9-Day RSI | 30.21 | |||||
14-Day RSI | 32.49 | |||||
3-1 Month Momentum % | -78.71 | |||||
6-1 Month Momentum % | -92.52 | |||||
12-1 Month Momentum % | -97.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.5 | |||||
Quick Ratio | 0.3 | |||||
Cash Ratio | 0.18 | |||||
Days Inventory | 798.59 | |||||
Days Sales Outstanding | 13.4 | |||||
Days Payable | 590.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -73.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.05 | |||||
Operating Margin % | -86.33 | |||||
Net Margin % | -115.49 | |||||
EBITDA Margin % | -111.4 | |||||
FCF Margin % | -25.53 | |||||
OCF Margin % | -25.53 | |||||
ROA % | -75.84 | |||||
ROIC % | -58.49 | |||||
3-Year ROIIC % | -249.66 | |||||
ROC (Joel Greenblatt) % | -286.48 | |||||
ROCE % | -350.39 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Free-Cash-Flow | 0.01 | |||||
Price-to-Operating-Cash-Flow | 0.01 | |||||
EV-to-EBIT | -1.32 | |||||
EV-to-EBITDA | -1.4 | |||||
EV-to-Revenue | 1.56 | |||||
EV-to-Forward-Revenue | 3.56 | |||||
EV-to-FCF | -6.12 | |||||
Earnings Yield (Greenblatt) % | -75.76 | |||||
FCF Yield % | -67.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JAGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jaguar Health Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29.544 | ||
| EPS (TTM) ($) | -1171.301 | ||
| Beta | -1.8832 | ||
| 3-Year Sharpe Ratio | -0.82 | ||
| 3-Year Sortino Ratio | -1.2 | ||
| Volatility % | 103.89 | ||
| 14-Day RSI | 32.49 | ||
| 14-Day ATR ($) | 0.331673 | ||
| 20-Day SMA ($) | 2.64375 | ||
| 12-1 Month Momentum % | -97.01 | ||
| 52-Week Range ($) | 2.12 - 97.649999 | ||
| Shares Outstanding (Mil) | 4.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jaguar Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jaguar Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-17 08:30 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-17 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| Jaguar\'s Presentation at the Life Sciences Virtual Investor Forum | 2026-06-24 13:00 | 2.56 (+2.40%) | ||
| Emerging Growth Conference; | 2026-06-10 12:35 | 2.82 (+5.22%) | ||
| Guidance call for 2026 | 2026-05-28 10:00 | 3.19 (+1.59%) | ||
| First quarter earnings conference call for 2026 | 2026-05-26 08:30 | 2.91 (-7.62%) | ||
| General meeting for 2026 | 2026-05-22 08:30 | 3.47 (+10.16%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 3.36 (-8.33%) |
Show
Entries
Jaguar Health Inc Frequently Asked Questions
What is Jaguar Health Inc(JAGX)'s stock price today?
The current price of JAGX is $2.31. The 52 week high of JAGX is $97.65 and 52 week low is $2.12.
When is next earnings date of Jaguar Health Inc(JAGX)?
The next earnings date of Jaguar Health Inc(JAGX) is 2026-08-14 Est..
Does Jaguar Health Inc(JAGX) pay dividends? If so, how much?
Jaguar Health Inc(JAGX) does not pay dividend.
Guru Commentaries on NAS:JAGX
No articles.
Press Release
Articles on Jaguar Health Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers